The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into ...

Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage ...

The nominal p-value was 0.0431 in a prespecified analysis of the 75% of participants who also received the approved Parkinson ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Prasinezumab missed statistical significance in delaying motor progression in early Parkinson's (HR=0.84, p=0.0657).

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better ...

While prasinezumab led to a numerical delay in motor progression without statistical significance, the effect was even more ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and commercialise monoclonal antibodies targeting α-syn, such as prasinezumab, ...

For this reason, people with Parkinson’s usually take levodopa in combination with another drug, carbidopa, that inhibits the break down. Researchers have been working to see how much of a role ...

Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson’s disease.

Roche has announced results from the Phase IIb PADOVA study evaluating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Wh ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s ...